Healthcare Marketing Agency | J&J/Janssen Case Study
See how Bryant Brown’s healthcare marketing specialists help J&J/Janssen educate schizophrenia and bipolar disorder patients.
Pharma advertising case studies, pharmaceutical advertising case studies, healthcare marketing agency case studies, healthcare marketing case studies, healthcare marketing agencies case studies, healthcare advertising agencies case studies, Johnson & Johnson marketing case studies, Janssen Healthcare Innovation marketing case studies, Johnson & Johnson marketing case studies, J&J marketing case studies
164
portfolio_page-template-default,single,single-portfolio_page,postid-164,ajax_fade,page_not_loaded,,qode-theme-ver-11.1,qode-theme-bridge,wpb-js-composer js-comp-ver-4.11.2.1,vc_responsive
 

Johnson & Johnson/Janssen Healthcare Innovation

Educating patients and providers about schizophrenia and bipolar disorder

Category
Pharmaceuticals
About This Project

Challenge:

Healthcare professionals need up-to-date tools they can use to educate bipolar disease patients and schizophrenia patients about their conditions, diagnoses, treatments, management of side effects, and ways to cope with triggers and relapses. Payers demanded these tools as part of a pull-through package for providers who prescribe J&J treatments for these conditions and for the patients who receive them.

 

Solution:

Bryant Brown helped conceive and create the “Recovery4today” schizophrenia and bipolar disease program. Each program packages interactive content for nine 2-hour counseling sessions. Each session combines a book and video. Bryant Brown produced all the video, including hours of interviews with actual patients plus custom animation sequences. In version 2.0, Bryant Brown also developed an online learning platform that repurposes existing content into web modules (more than 140 in all) that enable patients and families to interact with information at will or at the direction of their physician.

 

Results:

These healthcare marketing programs have become the new standard of care for counseling patients with schizophrenia and bipolar disease. Following the lead of, first, the participants in the pilot program (which included Sharp Health System in San Diego and Mount Sinai in New York), then early adopters, more and more hospitals and health systems are now implementing the program.

 

J&J’s antipsychotic brands have succeeded as well. Invega and Risperdal are blockbusters in this space, each with annual sales exceeding $1 billion.